CT-based tumour response criteria compared after combined treatment\ud for liver metastases of colorectal cancer

摘要

Purpose: The aim of this analysis is to compare different tumour response\udcriteria (TRC) after chemotherapy combined with bevacizumab in liver\udmetastases from colorectal cancer (mCRC) to ascertain the best early\udprognostic indicator of response.\udMethods and Materials: 103 target liver metastases from 65 mCRC patients\udtreated with chemoterapy plus bevacizumab were examined at the Istituto\udOncologico Veneto IOV-IRCSS (March 2008-January 2013). All patients had\udbaseline CT and at least one follow-up scan. Tumour response was\udretrospectively analyzed by two radiologists using RECIST1.1, modified Choi,\udand Chun morphologic criteria. Tumour response, classified as good (complete\udor partial response) or poor (stable or progressive disease), was compared\udwith progression-free survival (PFS) at first follow-up (t1) and time of best\udresponse. Interobserver agreement and concordance between TRC were\udmeasured.\udResults: At t1, 32.31% showed a good response according to RECIST1.1\ud(median PFS 11.1), 84.62% according to Choi (median PFS 10.8). These\udpercentages rose to 49.23% (median PFS 12.1) and 87.69% (median PFS\ud10.8), respectively, at the time of best response. According to Chun, 67.69%\udshowed a good response at the time of best response (median PFS 10.8). The\udChoi criteria detected a higher proportion of good responders at t1, showing a\udbetter correlation with PFS; all methods correlated with PFS at the time of best\udresponse.\udConclusion: The Choi criteria proved more consistent in the early detection of\udresponse in mCRC treated with chemotherapy plus bevacizumab,\udunderscoring the importance of using these criteria in the early assessment of\udresponse to combined treatment.